Melanoma vaccine: phase III trial finds 82.2% recurrence-free at two years

Melanoma vaccine: phase III trial finds 82.2% recurrence-free at two years

Rating
—/5 0 ratings
Follow us on Google News
Health & Lifestyle11 min read

Updated: 27 October 2026 la 00:12. Articolul a fost revizuit pentru a reflecta informațiile disponibile la această dată.

A personalised melanoma vaccine has produced one of the most significant results in cancer research in 2026. In a phase III clinical trial involving 1,137 adults, adding the experimental treatment intismeran autogene to pembrolizumab immunotherapy reduced the risk of cancer recurrence or death by 42% in relative terms, compared with pembrolizumab alone. At two years, 82.2% of patients given the combination were alive without recurrence, compared with 70.0% in the control group.

These figures, presented at ESMO 2026 and publicly detailed up to 26 October 2026, are promising but need to be understood correctly. The melanoma vaccine is not a preventive vaccine given to healthy people, and it is not yet an approved routine treatment. It is an individualised therapy made from the genetic features of the tumour of a patient who has already undergone surgery. This article explains who took part in the trial, how messenger RNA technology works, what the percentages mean and which questions remain unanswered.

For related information, see Neuropathic pain: an experimental peptide reduced pathological signals in mice. What the 2026 study shows, which examines an aspect directly related to this topic.

InfoBuz update: 26 October 2026. This medical information article is based on the phase III INTerpath-001 results and the official trial registration. It does not determine individual eligibility and does not replace advice from an oncologist.

What did researchers find in the leading melanoma vaccine trial?

The INTerpath-001 trial (NCT05933577) was randomised, double-blind and placebo-controlled. Patients had high-risk cutaneous melanoma at stages IIB–IV, and their tumour had been completely removed surgically. All received pembrolizumab, a PD-1 inhibitor immunotherapy drug; some also received the individualised mRNA treatment, while others received a placebo. The combination group included 757 patients, while the control group included 380.

After a median follow-up of 24.6 months, the results were statistically consistent for two endpoints: recurrence-free survival and distant metastasis-free survival. The results were presented as abstract LBA1 at the ESMO congress in October 2026. For independent detail, see The ASCO Post, 26 October 2026, and the technical data from CancerNetwork.

Measure Intismeran + pembrolizumab Pembrolizumab + placebo Interpretation
Patients assigned 757 380 Randomised phase III trial
Recurrence-free at 2 years (RFS) 82.2% 70.0% Absolute advantage of 12.2 percentage points
Free of distant metastasis at 2 years (DMFS) 88.5% 80.2% Absolute advantage of 8.3 percentage points
Risk of recurrence or death HR 0.58 Reference HR 1 42% relative reduction in hazard
Risk of distant metastasis or death HR 0.62 Reference HR 1 38% relative reduction in hazard

It is important not to mistake a 42% relative risk reduction for “42% more people cured”. The first figure comes from a statistical measure called a hazard ratio; it describes the ratio between instantaneous event rates over the course of the trial, rather than the simple difference between the percentages at two years. At the 24-month assessment, the actual difference in the proportion of people without recurrence was 12.2 percentage points: 82.2 minus 70.0. Both statistics matter, but they answer different questions.

How is a personalised mRNA vaccine made for one patient?

The word “vaccine” can suggest a product that is identical for millions of people, as is the case with many vaccines used to prevent infections. The technology here is different. Intismeran autogene, previously known as V940/mRNA-4157, is made for the individual patient using mutations found in their tumour. The approach is known as individualised neoantigen therapy.

  1. Tumour tissue is collected. After surgery, the laboratory analyses available material from the melanoma and a reference sample to distinguish tumour mutations from normal genetic variation.
  2. The genetic information is sequenced. Researchers identify tumour mutations and estimate which may produce protein fragments that the immune system can recognise.
  3. Relevant targets are selected. The platform can encode up to 34 neoantigens, which differ from one patient to another. Not every mutation is relevant enough to be included.
  4. The individualised messenger RNA is produced. The molecular message gives cells temporary instructions to produce the selected antigens. It does not alter the patient’s DNA.
  5. It is administered alongside immunotherapy. The treatment aims to train the T-cell response against any melanoma cells that may remain in the body.

The process is more complex than making a conventional vaccine because it requires a high-quality tumour sample, sequencing, target selection and personalised manufacturing. A promising result at a trial centre does not automatically mean broad availability, where time, cost and laboratory capacity may become constraints. Reporting on the results indicated that insufficient tumour material excluded some people assessed before randomisation. This matters when estimating future access.

Why is the vaccine combined with pembrolizumab?

The immune system can recognise some tumour cells, but melanoma has mechanisms that weaken this response. Pembrolizumab blocks the immune receptor PD-1, reducing one mechanism that can restrain lymphocyte activity. The vaccine, meanwhile, seeks to provide the immune system with a more precise list of targets in the patient’s tumour. Put simply, one helps identify targets, while the other may support immune cells’ ability to attack them.

This is a simplified explanation of the biological mechanism, not a guarantee that every patient will respond. Tumours differ, neoantigens are not equally easy to recognise, and immune defences vary from person to person. That is why a large randomised trial was needed: to determine whether a mechanism that looks promising in the laboratory produces measurable clinical results.

Who was included, and to whom cannot the findings be extrapolated?

Participants had high-risk cutaneous melanoma that had been completely resected. In other words, they had undergone surgery and the treatment was used in the adjuvant setting, to lower the risk that the disease would return. This is not the same situation as that of a healthy person seeking to prevent skin cancer, nor that of a patient with active, extensive disease who needs a different treatment regimen.

In oncology, melanoma stage, tumour thickness, lymph-node involvement and other features affect treatment strategy. Results from a trial in stages IIB–IV after resection cannot automatically be applied to very early melanoma, other skin cancers, or all patients with metastases that have not been treated surgically. A doctor must assess the data in relation to current oncology guidelines and the individual clinical situation.

How strong is the evidence, and what does phase III mean?

Clinical research generally progresses from early studies of safety and doses to larger studies designed to test clinical benefit. Phase III is important because it usually involves hundreds or thousands of participants, a comparison group and endpoints set in advance. In INTerpath-001, the inclusion of more than a thousand patients and comparison with standard treatment substantially strengthen the evidence relative to the smaller phase IIb study.

The earlier phase IIb KEYNOTE-942 study included around 157 patients and suggested a clinical benefit. That was an early signal, not final proof. The phase III results presented in October 2026 are confirmation in a broader population, but longer follow-up, full evaluation of the data and regulatory decisions are still needed. The official registration is available at ClinicalTrials.gov, NCT05933577.

What researchers have not yet shown: overall survival

The most difficult question is whether patients receiving the combination will live longer, rather than simply spend more time without recurrence. At the analysis presented at ESMO, data on overall survival (OS) were still immature. The estimated HR was 0.77, but the 0.45–1.31 confidence interval includes the possibility of no clear statistical benefit. It is therefore not correct to say that the study has already demonstrated a longer lifespan.

Recurrence-free survival nevertheless has real value for patients. A recurrence can mean procedures, investigations, further treatments, anxiety and a reduced quality of life. Even so, regulators and the medical community will continue to follow the duration of benefit, its impact on life and overall-survival outcomes.

What adverse effects were observed, and how common were they?

Any treatment that activates the immune system can cause adverse effects. In the combination group, the most commonly reported were fever (52.2%), injection-site pain (51.0%) and fatigue (38.5%). Many injection-related reactions were mild or temporary, but a symptom being common does not mean it is clinically unimportant. Comparative data show that fever and local pain were much more common in the group that also received intismeran.

According to the safety analysis, grade 3–5 treatment-related adverse events were reported in 14.2% of the combination group and 13.4% of the control group. Another statistic that includes serious adverse events regardless of causal attribution may have different values; the two categories should not be confused. Specialists will also monitor treatment discontinuations, immune-related events and long-term follow-up. Technical source: CancerNetwork – safety and subgroup analysis.

Patients already receiving immunotherapy should immediately tell their medical team about unusual symptoms, especially persistent diarrhoea, breathing difficulties, jaundice, significant pain or unexplained fever. This article does not recommend stopping or changing any prescribed treatment.

When could the therapy reach Romania, and what might it cost?

As of 26 October 2026, intismeran is an experimental therapy. Favourable phase III results do not mean that the medicine has already been approved in the European Union, reimbursed in Romania or can be requested immediately at any hospital. Its manufacturers, Moderna and MSD/Merck, have indicated that they intend to discuss it with regulators, but the timetable, price and actual terms of access have not been made public in a form that would allow promises to patients.

A personalised treatment also requires a specialised production chain: available tumour material, genomic-analysis laboratories, antigen selection, a manufacturing process for each patient and strict logistics. Even after possible approval, real availability could depend on infrastructure, eligibility criteria, price negotiations and decisions by the insurance system. For people seeking information about clinical trials, the starting point is the trial registry, together with their treating oncologist.

Could it also work for lung, kidney or bladder cancer?

Researchers are investigating individualised mRNA therapies in other tumours as well. However, melanoma has a distinct biological profile and may have a large number of mutations that generate neoantigens. The result in people who had surgery for melanoma does not show that the same formulation or strategy works in the same way in lung, kidney, pancreatic or other cancers. Each indication needs its own studies, designed for the relevant population and standard treatment.

The direction of personalised medicine extends beyond a single vaccine: selecting treatment based on the molecular profile, the risk of recurrence and patient characteristics. But this vision also raises questions about equitable access to diagnosis, the quality of biological samples and laboratory capacity. For a complementary analysis of the challenges in Romania, see the InfoBuz article on access to organised cancer screening.

Seven frequently asked questions about the personalised melanoma vaccine

Is the melanoma vaccine available in pharmacies?

No. Intismeran autogene is an individualised therapy still under clinical investigation, not a preventive vaccine sold through pharmacies. There is no vaccination schedule for healthy people using this product.

Does the vaccine permanently cure melanoma?

This has not been demonstrated. The data show a lower risk of recurrence or death during the period followed, after surgery and in combination with pembrolizumab. There is no guarantee that the disease will not return.

Does the 42% reduction mean that 42 out of 100 patients are saved?

No. It is a relative reduction in the hazard of recurrence or death. At two years, the difference between the recurrence-free proportions was 12.2 percentage points in a study of 1,137 participants.

Is the treatment different from HPV vaccines?

Yes. Preventive HPV vaccines aim to reduce the risk of infection with certain viral types and, consequently, some associated cancers. Intismeran is created after a melanoma diagnosis, using mutations in the patient’s own tumour, to reduce the risk of recurrence after surgery.

Why is pembrolizumab needed if there is a vaccine?

The trial tested adding the vaccine to pembrolizumab immunotherapy, not replacing it. These results do not allow the conclusion that the vaccine alone has the same effectiveness.

Can patients in Romania join the study?

Eligibility and recruitment depend on the protocol, active centres and the status of the trial. The NCT05933577 registry lists the study as active but not recruiting at the time of checking. Patients should discuss possible alternative trials with their oncologist; enrolment cannot be guaranteed.

Do the results already show that patients live longer?

Not yet. The overall-survival analysis has not provided definitive statistical evidence of a benefit. Follow-up continues.

Conclusion: an important advance, but not a universal cure

INTerpath-001 matters because a personalised treatment built from the genetic profile of each patient’s tumour achieved a positive result in a large phase III trial. The data point to a significant clinical advantage in preventing recurrence and distant metastases after surgery for high-risk melanoma. At the same time, premature promises should be avoided: overall survival has not yet been demonstrated, the therapy is not preventive and it is not approved for routine use. For patients and families, this is cause for hope supported by data, not certainty about an individual outcome.

Medical sources and studies

Etichete: cancer researchpembrolizumab immunotherapyINTerpath-001intismeran autogenemelanomaModerna Merckhealthclinical trials
Share this article
COMUNITATEA INFOBUZ

Discuția cititorilor

Ai o opinie sau o întrebare despre acest articol? Spune-ne ce crezi.

0 comentarii

Fii primul care deschide discuția.

Lasă un comentariu

Email address este vizibilă doar administratorilor și nu va fi publicată. Câmpurile marcate cu * sunt obligatorii.

Te rugăm să păstrezi un limbaj civilizat și să discuți la subiect. Comentariile spam sunt filtrate automat.